Role of Dynamic Parameters of 18F-DOPA PET/CT in Pediatric Gliomas.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
pubmed:
31
3
2022
medline:
7
5
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
PET with 18F-DOPA can be used to evaluate grading and aggressiveness of pediatric cerebral gliomas. However, standard uptake parameters may underperform in circumscribed lesions and in diffuse pontine gliomas. In this study, we tested whether dynamic 18F-DOPA PET could overcome these limitations. Patients with available dynamic 18F-DOPA PET were included retrospectively. Static parameters (tumor/striatum ratio [T/S] and tumor/cortex ratio [T/N]) and dynamic ones, calculated on the tumor time activity curve (TAC), including time-to-peak (TTP), slope steepness, the ratio between tumor and striatum TAC steepness (dynamic slope ratio [DSR]), and TAC shape (accumulation vs plateau), were evaluated as predictors of high/low grading (HG and LG) and of progression-free survival and overall survival. Fifteen patients were included; T/S, T/N, TTP, TAC slope steepness, and DSR were not significantly different between HG and LG. The accumulation TAC shape was more prevalent in the LG than in the HG group (75% vs 27%). On progression-free survival univariate analysis, TAC accumulation shape predicted longer survival (P < 0.001), whereas T/N and DSR showed borderline significance; on multivariate analyses, only TAC shape was retained (P < 0.01, Harrell C index, 0.93-0.95). On overall survival univariate analysis, T/N (P < 0.05), DSR (P < 0.05), and TAC "accumulating" shape predicted survival (P < 0.001); once more, only this last parameter was retained in the multivariate models (P < 0.05, Harrell C index, 0.86-0.89). Dynamic 18F-DOPA PET analysis outperforms the static parameter evaluation in grading assessment and survival prediction. Evaluation of the curve shape is a simple-to-use parameter with strong predictive power.
Identifiants
pubmed: 35353725
doi: 10.1097/RLU.0000000000004185
pii: 00003072-202206000-00007
doi:
Substances chimiques
Dihydroxyphenylalanine
63-84-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-524Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol . 2017;35:2370–2377.
Chen J, Dahiya SM. Update on circumscribed gliomas and glioneuronal tumors. Surg Pathol Clin . 2020;13:249–266.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol . 2021;23:1231–1251.
Jones DT, Mulholland SA, Pearson DM, et al. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. Acta Neuropathol . 2011;121:753–761.
Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol . 2010;28:3061–3068.
Chiang JC, Ellison DW. Molecular pathology of paediatric central nervous system tumours. J Pathol . 2017;241:159–172.
Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys . 2016;3:8.
Morana G, Piccardo A, Milanaccio C, et al. Value of 18 F-3,4-dihydroxyphenylalanine PET/MR image fusion in pediatric supratentorial infiltrative astrocytomas: a prospective pilot study. J Nucl Med . 2014;55:718–723.
Morana G, Piccardo A, Garrè ML, et al. Multimodal magnetic resonance imaging and 18 F- l -dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treated with bevacizumab. J Clin Oncol . 2013;31:e1–e5.
Piccardo A, Morana G, Puntoni M, et al. Diagnosis, treatment response, and prognosis: the role of 18 F-DOPA PET/CT in children affected by neuroblastoma in comparison with 123 I-mIBG scan: the first prospective study. J Nucl Med . 2020;61:367–374.
Piccardo A, Puntoni M, Lopci E, et al. Prognostic value of 18 F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur J Nucl Med Mol Imaging . 2014;41:1046–1056.
Ribeiro MJ, De Lonlay P, Delzescaux T, et al. Characterization of hyperinsulinism in infancy assessed with PET and 18 F-fluoro- l -DOPA. J Nucl Med . 2005;46:560–566.
Morana G, Piccardo A, Puntoni M, et al. Diagnostic and prognostic value of 18 F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study. Neuro Oncol . 2015;17:1637–1647.
Morana G, Piccardo A, Tortora D, et al. Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18 F-DOPA PET. Eur J Nucl Med Mol Imaging . 2017;44:2084–2093.
Piccardo A, Tortora D, Mascelli S, et al. Advanced MR imaging and 18 F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas. Eur J Nucl Med Mol Imaging . 2019;46:1685–1694.
Morana G, Tortora D, Bottoni G, et al. Correlation of multimodal 18 F-DOPA PET and conventional MRI with treatment response and survival in children with diffuse intrinsic pontine gliomas. Theranostics . 2020;10:11881–11891.
Ponisio MR, McConathy JE, Dahiya SM, et al. Dynamic 18 F-FDOPA-PET/MRI for the preoperative evaluation of gliomas: correlation with stereotactic histopathology. Neurooncol Pract . 2020;7:656–667.
Nioche C, Soret M, Gontier E, et al. Evaluation of quantitative criteria for glioma grading with static and dynamic 18 F-FDopa PET/CT. Clin Nucl Med . 2013;38:81–87.
Chen W, Silverman DH, Delaloye S, et al. 18 F-FDOPA PET imaging of brain tumors: comparison study with 18 F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med . 2006;47:904–911.
Schiepers C, Chen W, Cloughesy T, et al. 18 F-FDOPA kinetics in brain tumors. J Nucl Med . 2007;48:1651–1661.
Ginet M, Zaragori T, Marie PY, et al. Integration of dynamic parameters in the analysis of 18 F-FDopa PET imaging improves the prediction of molecular features of gliomas. Eur J Nucl Med Mol Imaging . 2020;47:1381–1390.
Cooney TM, Cohen KJ, Guimaraes CV, et al. Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol . 2020;21:e330–e336.
Erker C, Tamrazi B, Poussaint TY, et al. Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol . 2020;21:e317–e329.
Fangusaro J, Witt O, Hernáiz Driever P, et al. Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol . 2020;21:e305–e316.
Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ 18 F]FDG: version 1.0. Eur J Nucl Med Mol Imaging . 2019;46:540–557.
Kratochwil C, Combs SE, Leotta K, et al. Intra-individual comparison of 18 F-FET and 18 F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol . 2014;16:434–440.
Morana G, Piccardo A, Garrè ML, et al. 18 F-DOPA uptake of developmental venous anomalies in children with brain tumors. Clin Nucl Med . 2016;41:e351–e352.
Nioche C, Orlhac F, Boughdad S, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res . 2018;78:4786–4789.
Dunkl V, Cleff C, Stoffels G, et al. The usefulness of dynamic O -(2- 18 F-fluoroethyl)- l -tyrosine PET in the clinical evaluation of brain tumors in children and adolescents. J Nucl Med . 2015;56:88–92.
Marner L, Lundemann M, Sehested A, et al. Diagnostic accuracy and clinical impact of [ 18 F]FET PET in childhood CNS tumors. Neuro Oncol . 2021;23:2107–2116.
Fraioli F, Shankar A, Hyare H, et al. The use of multiparametric 18 F-fluoro- l -3,4-dihydroxy-phenylalanine PET/MRI in post-therapy assessment of patients with gliomas. Nucl Med Commun . 2020;41:517–525.
Aldape K, Zadeh G, Mansouri S, et al. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol . 2015;129:829–848.
Niida H, Takeuchi S, Tanaka R, et al. Angiogenesis in microvascular endothelial cells induced by glioma cells and inhibited by tumor necrosis factor in vitro. Neurol Med Chir (Tokyo) . 1995;35:209–214.
Puget S, Alshehri A, Beccaria K, et al. Pediatric infratentorial ganglioglioma. Childs Nerv Syst . 2015;31:1707–1716.
Luo CB, Teng MM, Chen SS, et al. Intracranial ganglioglioma: CT and MRI findings. Kaohsiung J Med Sci . 1997;13:467–474.
Parenrengi MA, Aji YK. Multiple lesions accompanied by postoperative spontaneous intracystic hemorrhage in a pediatric patient with Pilocytic astrocytoma. Asian J Neurosurg . 2020;15:409–413.
El-Khouly FE, Veldhuijzen van Zanten SEM, Santa-Maria Lopez V, et al. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? J Neurooncol . 2019;145:177–184.
Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the international and European Society for Pediatric Oncology DIPG registries. J Clin Oncol . 2018;36:1963–1972.
Werbrouck C, Evangelista CCS, Lobón-Iglesias MJ, et al. TP53 pathway alterations drive radioresistance in diffuse intrinsic pontine gliomas (DIPG). Clin Cancer Res . 2019;25:6788–6800.
Bag AK, Wing MN, Sabin ND, et al. [ 11 C]-Methionine PET for identification of pediatric high-grade glioma recurrence. J Nucl Med . 2021;jnumed.120.261891.
Morana G, Puntoni M, Garrè ML, et al. Ability of (18)F-DOPA PET/CT and fused (18)F-DOPA PET/MRI to assess striatal involvement in paediatric glioma. Eur J Nucl Med Mol Imaging . 2016;43:1664–1672.